Insider Transactions
| Date | Name | Title | Type | Shares Traded | Price Range |
|---|---|---|---|---|---|
| Jun 23, 2021 |
Chief Medical Officer
|
Chief Medical Officer | Other acquisition or disposition | -- | -- |
| Jun 22, 2021 |
Chief Medical Officer
|
Chief Medical Officer | Open market or private sale of non-derivative or derivative security | 5,821 | $4.09 |
| Jun 22, 2021 |
Chief Legal Officer
|
Chief Legal Officer | Open market or private sale of non-derivative or derivative security | 4,500 | $4.16 |
| Jun 22, 2021 |
Chief Legal Officer
|
Chief Legal Officer | Other acquisition or disposition | -- | -- |
| Jun 21, 2021 |
Chief Legal Officer
|
Chief Legal Officer | Open market or private sale of non-derivative or derivative security | 3,735 | $4.27 |
| Jun 18, 2021 |
Director
|
Director | Open market or private sale of non-derivative or derivative security | 9,000 | $4.24 |
| Jun 18, 2021 |
Director
|
Director | Open market or private sale of non-derivative or derivative security | 12,000 | $4.24 |
| Jun 18, 2021 |
Director
|
Director | Open market or private sale of non-derivative or derivative security | 9,000 | $4.24 |
| Jun 17, 2021 |
Director
|
Director | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 14,277 | -- |
| Jun 17, 2021 |
Director
|
Director | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 67,804 | -- |
| Jun 17, 2021 |
Director
|
Director | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 14,277 | -- |
| Jun 17, 2021 |
Director
|
Director | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 67,804 | -- |
| Jun 17, 2021 |
Director
|
Director | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 14,277 | -- |
| Jun 17, 2021 |
Director
|
Director | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 67,804 | -- |
| Jun 17, 2021 |
Director
|
Director | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 14,277 | -- |
| Jun 17, 2021 |
Director
|
Director | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 67,804 | -- |
| Jun 17, 2021 |
Director
|
Director | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 14,277 | -- |
| Jun 17, 2021 |
Director
|
Director | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 67,804 | -- |
| Jun 17, 2021 |
Director
|
Director | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 14,277 | -- |
| Jun 17, 2021 |
Director
|
Director | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 67,804 | -- |
| May 14, 2021 |
Chief Legal Officer
|
Chief Legal Officer | Open market or private sale of non-derivative or derivative security | 525 | $3.07 |
| May 14, 2021 |
Chief Legal Officer
|
Chief Legal Officer | Other acquisition or disposition | -- | -- |
| May 14, 2021 |
EVP, COO & CCO
|
EVP, COO & CCO | Open market or private sale of non-derivative or derivative security | 2,250 | $3.07 |
| May 14, 2021 |
EVP, COO & CCO
|
EVP, COO & CCO | Other acquisition or disposition | -- | -- |
| May 13, 2021 |
Chief Legal Officer
|
Chief Legal Officer | Open market or private sale of non-derivative or derivative security | 434 | $3.09 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.